Filana Therapeutics (FLNA) Current Deferred Revenue (2010 - 2013)

Filana Therapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $7.8 million in Q3 2013.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $7.8 million in Q3 2013; TTM through Sep 2013 was $7.8 million, a N/A change from a year earlier, with the FY2012 full-year figure at $7.8 million, down 28.13% from the prior year.
• Current Deferred Revenue was $7.8 million for Q3 2013 at Filana Therapeutics, roughly flat from $7.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $10.9 million in Q4 2010, with the low at $7.8 million in Q4 2012.
• Average Current Deferred Revenue over 4 years is $9.5 million, with a median of $10.9 million recorded in 2010.
• The sharpest annual moves came in 2011 and 2012: Current Deferred Revenue changed 0.0% in 2011, then retreated 28.13% in 2012.
• Over 4 years, Current Deferred Revenue stood at $10.9 million in 2010, then changed by 0.0% to $10.9 million in 2011, then declined by 28.13% to $7.8 million in 2012, then changed by 0.0% to $7.8 million in 2013.
• The last three Current Deferred Revenue figures came in at $7.8 million (Q3 2013), $7.8 million (Q2 2013), and $7.8 million (Q1 2013), per Business Quant data.